[Skip to content]

Cancer

Cancer

brain scan

The Cancer page covers both primary and secondary care, including screening, prevention, diagnosis and treatment. 

View the contents of the newsfeed below or subscribe using the link below. 

Search this subject

Search

Latest News about Cancer

  • Single routine offer of a blood test for prostate cancer did not save livesThis expert commentary is provided for a study which found no difference in rates of prostate cancer death for screening vs no screening. Screening may increase diagnoses but does not reduce deaths. The commentators say that trials like this one challenge "advances" that appear common sense but may do harm. 14/06/2018
  • Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgeryThis expert commentary is provided for an RCT which found a similar three year progression free survival for 3 months and 6 months of chemotherapy. Most guidelines recommend six months treatment, this study gives the potential to improve acceptability and uptake of treatment 14/06/2018
  • Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancerThis research article is the science behind the headline "Remarkable therapy beats terminal cancer". The research presents a patient with chemorefractory hormone receptor (HR)-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins—SLC3A2, KIAA0368, CADPS2 and CTSB. Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months. The authors state it represents a new immunotherapy approach for the treatment of these patients. 08/06/2018
  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerThis research article is the science behind the headlines "Breast cancer: Test means fewer women will need chemotherapy". The research concludes that the recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. 08/06/2018
  • Missed opportunities: advance care planning reportThis report warns that reluctance to talk honestly about death is preventing people with cancer from dying 'well'. It calls for Governments across the UK to honour their commitments to ensuring Advance Care Planning is used as an important part of a person-centred health service, so that people approaching the end of their lives receive the best care possible and their wishes for death and dying are fulfilled 21/05/2018
  • Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016This research has led to a Practice Changing Update on DynaMed Plus. Itarticle concludes that CHOP plus 131 I tositumomab and CHOP plus rituximab may have similar 5- and 10-year overall survival, but CHOP plus rituximab may improve 10-year progression-free survival in adults with advanced follicular lymphoma. 16/05/2018
  • Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerThis research article has led to a Practice Update in DynaMed Plus. It concludes that addition of pembrolizumab to chemotherapy with pemetrexed and platinum-based drug increases overall survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer. 09/05/2018
  • Systemic treatments for metastatic cutaneous melanomaThis Systematic Review found high-quality evidence that many treatments offer better efficacy than chemotherapy, especially recently implemented treatments, such as small-molecule targeted drugs, which are used to treat melanoma with specific gene mutations. 09/05/2018